Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CHINA OILFIELD
02883
5
KUNLUN ENERGY
00135
HK Stock MarketDetailed Quotes
HENGRUI PHARMA (01276)
- 66.850
- -0.050-0.07%
Not Open Apr 22 16:07 CST
443.70BMarket Cap48.27P/E (TTM)
67.450High65.950Low1.45MVolume67.000Open66.900Prev Close96.54MTurnover0.56%Turnover Ratio51.98P/E (Static)6.64BShares95.20052wk High6.16P/B17.26BFloat Cap52.50052wk Low--Dividend TTM258.20MShs Float95.200Historical High--Dividend LFY2.24%Range %52.500Historical Low66.619Avg Price200Lot Size--Div Yield TTM--Div Yield LFY
HENGRUI PHARMA (01276) Income Statement
All
YOY
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 12.98%8.14B | 13.02%31.63B | 14.85%23.19B | --15.76B | --7.21B | 22.63%27.98B | 18.67%20.19B | 7.26%22.82B | --17.01B | --21.28B |
| Operating income | 12.98%8.14B | 13.02%31.63B | 14.85%23.19B | 15.76B | 7.21B | 22.63%27.98B | 18.67%20.19B | 7.26%22.82B | 17.01B | 21.28B |
| Cost of sales | ---- | -13.37%-4.36B | ---- | ---2.11B | ---- | -9.16%-3.85B | ---- | -1.11%-3.53B | ---2.66B | ---3.49B |
| Operating expenses | -2.09%-1.09B | -13.37%-4.36B | -12.79%-3.2B | -2.11B | -1.07B | -9.16%-3.85B | -6.61%-2.83B | -1.11%-3.53B | -2.66B | -3.49B |
| Gross profit | 14.87%7.05B | 12.97%27.27B | 15.19%19.99B | 13.65B | 6.14B | 25.09%24.14B | 20.90%17.36B | 8.47%19.29B | 14.36B | 17.79B |
| Selling expenses | -11.66%-2.2B | -9.24%-9.11B | -10.99%-6.78B | ---4.39B | ---1.97B | -10.02%-8.34B | -12.96%-6.11B | -3.12%-7.58B | ---5.41B | ---7.35B |
| Administrative expenses | -5.38%-617.63M | -9.12%-3.07B | -13.49%-2.13B | ---1.41B | ---586.08M | -6.45%-2.82B | -0.92%-1.87B | -5.86%-2.64B | ---1.86B | ---2.5B |
| Research and development expenses | -7.66%-1.65B | -5.75%-6.96B | -8.72%-4.95B | ---3.23B | ---1.53B | -32.88%-6.58B | -22.10%-4.55B | -1.38%-4.95B | ---3.73B | ---4.89B |
| Profit from asset sales | 549.82%6.75M | ---- | 14.13%2.45M | ---- | --1.04M | ---- | --2.15M | ---- | ---- | ---- |
| Revaluation surplus | 1,084.23%129.06M | ---- | 926.26%97.8M | ---- | ---13.11M | ---- | --9.53M | ---- | ---- | ---- |
| -Changes in the fair value of other assets | 1,084.23%129.06M | ---- | 926.26%97.8M | ---- | ---13.11M | ---- | --9.53M | ---- | ---- | ---- |
| Impairment and provision | -496.72%-24.39M | ---- | -575.24%-34.02M | ---- | --6.15M | ---- | ---5.04M | ---- | ---- | ---- |
| -Other impairment is provision | -496.72%-24.39M | ---- | -575.24%-34.02M | ---- | --6.15M | ---- | ---5.04M | ---- | ---- | ---- |
| Special items of operating profit | -107.67%-1.61M | -12.94%691.66M | 19.44%285.84M | --485.1M | --20.99M | 26.75%794.48M | -52.07%239.32M | -36.17%626.79M | --499.31M | --981.95M |
| Operating profit | 31.15%2.63B | 22.54%8.82B | 28.46%6.29B | 5.1B | 2.01B | 51.65%7.2B | 26.74%4.9B | 17.53%4.75B | 3.86B | 4.04B |
| Financing income | 319.08%322.96M | ---- | 1.18%496.73M | ---- | --77.07M | ---- | --490.92M | ---- | ---- | ---- |
| Financing cost | 95.90%-448.28K | -158.12%-14.35M | -272.79%-12.35M | ---11.66M | ---10.92M | 5.86%-5.56M | 30.14%-3.31M | 9.03%-5.91M | ---4.74M | ---6.49M |
| Share of profits of associates | ---- | -350.13%-97.14M | ---- | ---41.47M | ---- | 70.31%-21.58M | ---- | -15.40%-72.7M | ---47.12M | ---63M |
| Special items of earning before tax | -387.43%-50.58M | ---- | 17.81%-212.5M | ---- | ---10.38M | ---- | ---258.55M | ---- | ---- | ---- |
| Earning before tax | 23.19%2.56B | 21.45%8.71B | 26.05%6.41B | 5.05B | 2.08B | 53.62%7.17B | 33.43%5.09B | 17.60%4.67B | 3.81B | 3.97B |
| Tax | ---- | -18.97%-990.62M | ---- | ---596.26M | ---- | -113.90%-832.7M | ---- | -153.85%-389.29M | ---361.35M | ---153.35M |
| After-tax profit from continuing operations | 21.56%2.28B | 21.78%7.72B | 24.78%5.76B | 4.45B | 1.88B | 48.14%6.34B | 33.77%4.62B | 12.13%4.28B | 3.45B | 3.82B |
| Earning after tax | 21.56%2.28B | 21.78%7.72B | 24.78%5.76B | 4.45B | 1.88B | 48.14%6.34B | 33.77%4.62B | 12.13%4.28B | 3.45B | 3.82B |
| Minority profit | -153.37%-1.27M | 1,170.73%5.95M | 379.31%9.07M | --4.56M | --2.39M | 101.90%468K | 85.73%-3.25M | 73.02%-24.62M | ---22.75M | ---91.23M |
| Profit attributable to shareholders | 21.78%2.28B | 21.69%7.71B | 24.50%5.75B | 4.45B | 1.87B | 47.28%6.34B | 32.98%4.62B | 10.14%4.3B | 3.47B | 3.91B |
| Basic earnings per share | 13.33%0.34 | 19.00%1.19 | 21.92%0.89 | 0.7 | 0.3 | 47.06%1 | 32.73%0.73 | 11.48%0.68 | 0.55 | 0.61 |
| Diluted earnings per share | 13.33%0.34 | 18.00%1.18 | 21.92%0.89 | 0.7 | 0.3 | 47.06%1 | 32.73%0.73 | 11.48%0.68 | 0.55 | 0.61 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | IAS | IAS |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Ernst & Young | -- | -- | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome
牛牛課堂
Oct 13, 2025 18:05
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
Food流油
Apr 14, 2025 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"